<DOC>
	<DOCNO>NCT02515773</DOCNO>
	<brief_summary>A prospective , large , pragmatic , randomized trial study impact METFORMIN healthy lifestyle intervention ( LIFE ) vs. LIFE alone patient-centered outcome body weight , SGA-adherence satisfaction , psychiatric symptom burden ( e.g . mood/anxiety ) , Quality Life .</brief_summary>
	<brief_title>Metformin Overweight &amp; OBese ChILdren Adolescents With BDS Treated With SGAs</brief_title>
	<detailed_description>The investigator propose recruit 1800 overweight/obese youth Bipolar Spectrum Disorder ( BSD ) prescribe second generation anti psychotic ( SGAs ) least 24 public private mental health practice Greater Cincinnati New York City region , ( approximately 900 ~12 Cincinnati region ~12 Long Island/New York mental health treatment site ) participate propose patient-centered large pragmatic trial examine effectiveness MET LIFE vs. LIFE alone . Patients eligible age 8-17 year old , inclusive , overweight obese ( BMI &gt; 85 % ) , continue start treatment least one SGA ( i.e. , olanzapine , clozapine , risperidone , quetiapine , aripiprazole , ziprasidone , iloperidone , lurasidone , paliperidone , asenapine ) clinical diagnosis BSD ( bipolar I II disorder , cyclothymia , bipolar mood disorder otherwise specify [ Diagnostic Statistical Manual Mental Disorders V ( DSM-5 ) , specify bipolar mood disorder ) . The enrollment rate 2-3 patients/month/site recruitment time 30 month .</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Inpatient outpatient age 817 year inclusive ; 2 . Fluent English ; 3 . Diagnosed clinician bipolar spectrum disorder ( BSD ) , i.e. , bipolar I , bipolar II , bipolar mood disorder otherwise specify , cyclothymic disorder specify bipolar mood disorder ; 4 . Body mass index &gt; 85 % ile age sex standard growth chart ; 5 . Received new ongoing prescription least one SGA ( i.e. , olanzapine , clozapine , risperidone , quetiapine , aripiprazole , ziprasidone , iloperidone , lurasidone , paliperidone , asenapine ) 1 . Prior intolerance ineffective exposure Metformin ( MET ) ; No exposure past 12 month permit ; 2 . Major neurological medical illness affect weight gain ( e.g. , unstable thyroid disease ) require systemic medication might impact weight glucose regulation ( e.g. , diabetes mellitus [ insulin ] , chronic renal failure [ steroid ] ) ; 3 . Fasting glucose &gt; 125 mg/dL 2 occasion screen indicate need prompt treatment ; 4 . Serum creatinine â‰¥1.3 mg/dL 2 occasion screen and/or followup , indicate potential impairment renal functioning ; 5 . Pregnant breast feeding ; 6 . Children caregiver unable complete assessment child reason ;</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>